These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35422340)

  • 1. Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias.
    Jerves T; Blau N; Ferreira CR
    Mol Genet Metab; 2022 Jun; 136(2):118-124. PubMed ID: 35422340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma.
    Blackburn PR; Hickey RD; Nace RA; Giama NH; Kraft DL; Bordner AJ; Chaiteerakij R; McCormick JB; Radulovic M; Graham RP; Torbenson MS; Tortorelli S; Scott CR; Lindor NM; Milliner DS; Oglesbee D; Al-Qabandi W; Grompe M; Gavrilov DK; El-Youssef M; Clark KJ; Atwal PS; Roberts LR; Klee EW; Ekker SC
    Hum Mutat; 2016 Oct; 37(10):1097-105. PubMed ID: 27397503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biochemical footprints of inherited metabolic diseases. II. Metabolic liver diseases.
    Ferreira CR; Cassiman D; Blau N
    Mol Genet Metab; 2019 Jun; 127(2):117-121. PubMed ID: 31005404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment.
    van Spronsen FJ; Bijleveld CM; van Maldegem BT; Wijburg FA
    J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):90-3. PubMed ID: 15625434
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP.
    van Ginkel WG; Gouw AS; van der Jagt EJ; de Jong KP; Verkade HJ; van Spronsen FJ
    Pediatrics; 2015 Mar; 135(3):e749-52. PubMed ID: 25667247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biochemical footprints of inherited metabolic diseases. I. Movement disorders.
    Ferreira CR; Hoffmann GF; Blau N
    Mol Genet Metab; 2019 May; 127(1):28-30. PubMed ID: 30928149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of HCC: genetic heterogeneity and complex genetics.
    Dragani TA
    J Hepatol; 2010 Feb; 52(2):252-7. PubMed ID: 20022654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biochemical footprints of inherited metabolic diseases. IV. Metabolic cardiovascular disease.
    Ferreira CR; Blau N
    Mol Genet Metab; 2021 Feb; 132(2):112-118. PubMed ID: 33388235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Silent" tyrosinemia presenting as hepatocellular carcinoma in a 10-year-old girl.
    Castilloux J; Laberge AM; Martin SR; Lallier M; Marchand V
    J Pediatr Gastroenterol Nutr; 2007 Mar; 44(3):375-7. PubMed ID: 17325560
    [No Abstract]   [Full Text] [Related]  

  • 10. Stereotactic radiofrequency ablation for liver tumors in inherited metabolic disorders.
    Karall D; Scholl-Bürgi S; Widmann G; Albrecht U; Niedermayr K; Maurer K; Ausserer B; Huemer M; Bale R
    Cardiovasc Intervent Radiol; 2014 Aug; 37(4):1027-33. PubMed ID: 24149831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.
    Bhushan S; Noble C; Balouch F; Lewindon P; Lampe G; Hodgkinson P; McGill J; Ee L
    Pediatr Transplant; 2022 Nov; 26(7):e14334. PubMed ID: 35698261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biochemical footprints of inherited metabolic disease. V. Cerebral palsy phenotypes.
    Horvath GA; Blau N; Ferreira CR
    Mol Genet Metab; 2022 Dec; 137(4):445-448. PubMed ID: 33775522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
    Gjorgjieva M; Calderaro J; Monteillet L; Silva M; Raffin M; Brevet M; Romestaing C; Roussel D; Zucman-Rossi J; Mithieux G; Rajas F
    J Hepatol; 2018 Nov; 69(5):1074-1087. PubMed ID: 30193922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
    An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosinemia.
    Lam R; Armenta A; Kilic M; Karpen SJ; Scaglia F; Seu P; Goss JA
    Liver Transpl; 2002 May; 8(5):500-1. PubMed ID: 12004353
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and biochemical footprints of inherited metabolic diseases. III. Psychiatric presentations.
    Horvath GA; Stowe RM; Ferreira CR; Blau N
    Mol Genet Metab; 2020 May; 130(1):1-6. PubMed ID: 32122747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
    Morrow G; Tanguay RM
    Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
    Nobili V; Jenkner A; Francalanci P; Castellano A; Holme E; Callea F; Dionisi-Vici C
    Pediatrics; 2010 Jul; 126(1):e235-8. PubMed ID: 20547648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genes and viruses in hepatobiliary neoplasia.
    Reeves ME; DeMatteo RP
    Semin Surg Oncol; 2000; 19(2):84-93. PubMed ID: 11126384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary Tyrosinemia Type 1 in Turkey.
    Aktuglu-Zeybek AC; Kiykim E; Cansever MS
    Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.